Meeting
2014 ASCO Annual Meeting
Results of stage 1 of the oparatic trial: A phase I study of olaparib in combination with temozolomide in patients with relapsed glioblastoma.
Authors
Anthony J. Chalmers
University of Glasgow, Glasgow, United Kingdom
Anthony J. Chalmers , Alan Jackson , Helen Swaisland , William Stewart , Sarah E. R. Halford , L Rhoda Molife , Darren R Hargrave , Alex McCormick
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Highlights Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Clinical Trial Registration Number
NCT01390571
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 2025)
DOI
10.1200/jco.2014.32.15_suppl.2025
Abstract #
2025
Poster Bd #
16
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Phase I clinical trials evaluating olaparib in combination with radiotherapy (RT) and/or temozolomide (TMZ) in glioblastoma patients: Results of OPARATIC and PARADIGM phase I and early results of PARADIGM-2.
First Author: Anthony J. Chalmers
Poster
2017 ASCO Annual Meeting
Results of the OPARATIC trial: A phase I dose escalation study of olaparib in combination with temozolomide (TMZ) in patients with relapsed glioblastoma (GBM).
First Author: Sarah E. R. Halford
Poster
2013 ASCO Annual Meeting
Phase I adult brain tumor consortium (ABTC) trial of ABT-888 (veliparib), temozolomide (TMZ), and radiotherapy (RT) for newly diagnosed glioblastoma multiforme (GBM) including pharmacokinetic (PK) data.
First Author: Lawrence Kleinberg
Poster
2013 ASCO Annual Meeting
A phase I clinical trial of veliparib and temozolomide in children with recurrent central nervous system tumors: A Pediatric Brain Tumor Consortium report.
First Author: Jack M. Su